Summary
The effect of salicylate treatment on the kidney, particularly medullary function, was investigated. In a retrospective analysis patients with rheumatoid arthritis (RA) treated with high doses of salicylates were shown to have inferior urinary concentrating power and increased excretion of N-acetyl-3-D-glucosaminidase (NAG) when compared with patients who had not received salicylate treatment. A prospective study of renal function in healthy people and patients with RA starting salicylate in therapeutic doses showed that while epithelial cell excretion was only transiently raised in both groups the excretion of NAG was increased in all cases at three days and this increase was sustained at 10 days, all values being much higher in the patients than in the healthy subjects. Thus salicylate treatment does cause renal tubular damage but this damage results in only minimal impairment of function and does not constitute a reason for withholding salicylate treatment.
Introduction
Death from renal failure is much more common in patients with rheumatoid arthritis (RA) than in the general population ' and definite renal disease has been noted in no 
Patients and methods
Two studies were performed. (1) In a retrospective study we investigated renal function in 20 patients with long-standing RA, 10 of whom had received large quantities of salicylate (average total 14 3 kg) and 10 of whom had never received systematic salicylate treatment (average total 0-125 kg). The two groups were matched for age, sex, and duration of disease (table I) and all other drugs taken were recorded. (2) We also performed a prospective study of renal glomerular and tubular function in patients receiving salicylate treatment for the first time. Eight patients with RA and 10 healthy volunteers were observed. Salicylate was administered as aloxiprin two tablets four times daily-a total daily dose of 4 g of salicylate.
Renal function tests were carried out before starting salicylate and again three and 10 days later. 
3-D-glucosaminidase (NAG)
. Acid-load handling was evaluated by the method of Wrong and Davies.5 Maximum concentrating power was estimated by recording urinary osmolarity after 12 hours' overnight water deprivation and after intramuscular pitressin, 5 units, given at 9 pm. The bladder was emptied at 6 am and a specimen collected at 8 am. Epithelial cell and white blood cell counts were expressed per high power field (HPF) from an uncentrifuged specimen of urine and NAG was analysed by the method described by Tucker et a16 and expressed as nmol h-1 mg creatinine-1.
Results
In the retrospective study (table II) there was a significant decrease in maximum urinary concentrating power in the patients who had received high-dose salicylate treatment, although concentrating power was generally lower than normal in both groups. The minimum pH NAG (nmol h-1 mg creatinine-1)..
Glucose and amino-acids recorded in both groups was higher than might have been expected, but in both groups the results were affected by the difficulty that some subjects had in ingesting the acid load. The average excretion of NAG was high in both groups (the upper limit of normal is accepted as 100 nmol h-1 mg creatinine-1),6 but the high-salicylate group had significantly higher levels. No significant differences were observed in glomerular filtration rate (GFR), cellular excretion, or protein, amino-acid, or glucose excretion.
In the prospective study ( In the retrospective study the use of other drugs such as gold, penicillamine, corticosteroids, and non-steroidal anti-inflammatory drugs was analysed. Although there were slightly more patients who had received chrysotherapy in the salicylate-treated group, analysis of the figures for NAG excretion and maximum concentrating power did not suggest that this form of treatment caused impairment of medullary function (table IV) and the same was found for corticosteroids. A study of NAG excretion in patients with non-inflammatory joint disease has shown that non-steroidal anti-inflammatory drugs do not increase enzyme excretion,18 and possibly also there is some form of continuing renal damage in patients with RA irrespective of their treatment. ' 9 It seems that salicylate may cause a mild disturbance of function in addition to this. The functional changes would be consistent in severity with the evidence of chronic interstitial nephritis seen in biopsy and necropsy material. Nevertheless, in view of the lack of evidence that salicylates cause any severe renal damage there is no need to deny patients their undoubted therapeutic benefits because of the fear of causing renal damage. Summary A controlled randomised trial was carried out to evaluate the efficacy of BCG immunotherapy in preventing relapse in patients with Burkitt's lymphoma in whom remission had been induced with cyclophosphamide. Twenty-one patients were treated with BCG, and 19 were controls. Eleven patients in each group relapsed during a follow-up period long enough to make it unlikely that further relapses would occur. There were no significant differences in the length of remission or the site of relapse that could be attributed to treatment. Eleven patients died: of these none of the six patients in the BCG group but all of the five in the control group had stage D lymphomas.
BCG treatment increased the rate of recovery from tumour-induced immunosuppression, but within the BCG group immunocompetence improved most rapidly in the patients who relapsed-a finding that appears to contradict the tenet rationalising the use of immunological adjuvants as treatment. Introduction Burkitt's lymphoma responds dramatically to chemotherapy, and the high frequency of sustained remission indicates that a cure is possible.' Nevertheless, about two-thirds of patients relapse during the first year, and about half of these eventually die with a tumour resistant to chemotherapy.' 2 Attempts to prevent relapse by intensifying chemotherapy have so far proved unsuccessful.' 3 4Evidence for the existance of tumourdirected immunological reactions and their correlation with clinical status',-prompted us to evaluate immunotherapy in a controlled randomised trial. We report here the effect of nonspecific immunostimulation with BCG on the clinical course of patients in whom remission had been induced by a standard moderate amount of chemotherapy. 
